Guggenheim Capital LLC lifted its position in shares of Perrigo Company plc (NYSE:PRGO – Free Report) by 50.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,844 shares of the company’s stock after purchasing an additional 15,648 shares during the period. Guggenheim Capital LLC’s holdings in Perrigo were worth $1,204,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the business. Headlands Technologies LLC lifted its holdings in Perrigo by 1,942.0% in the 4th quarter. Headlands Technologies LLC now owns 1,409 shares of the company’s stock worth $36,000 after buying an additional 1,340 shares during the period. Versant Capital Management Inc purchased a new stake in Perrigo in the fourth quarter worth $45,000. GAMMA Investing LLC lifted its stake in Perrigo by 93.7% in the fourth quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $49,000 after acquiring an additional 929 shares during the period. Central Pacific Bank Trust Division increased its position in Perrigo by 33.3% during the 4th quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company’s stock valued at $51,000 after purchasing an additional 500 shares during the period. Finally, Venturi Wealth Management LLC raised its holdings in Perrigo by 97.8% in the 4th quarter. Venturi Wealth Management LLC now owns 4,215 shares of the company’s stock worth $108,000 after purchasing an additional 2,084 shares in the last quarter. 95.91% of the stock is owned by institutional investors.
Perrigo Price Performance
PRGO stock opened at $24.41 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. The firm has a market capitalization of $3.33 billion, a price-to-earnings ratio of -20.86 and a beta of 0.49. The firm has a 50 day moving average price of $26.49 and a 200-day moving average price of $26.05. Perrigo Company plc has a 52-week low of $23.14 and a 52-week high of $33.46.
Perrigo Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 25th. Shareholders of record on Friday, March 7th were issued a $0.29 dividend. The ex-dividend date was Friday, March 7th. This is a boost from Perrigo’s previous quarterly dividend of $0.28. This represents a $1.16 annualized dividend and a yield of 4.75%. Perrigo’s payout ratio is -92.80%.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on PRGO shares. Piper Sandler lowered shares of Perrigo from an “overweight” rating to a “neutral” rating and cut their target price for the company from $34.00 to $27.00 in a research note on Monday, January 6th. Argus lowered Perrigo from a “buy” rating to a “hold” rating in a research report on Tuesday, January 14th. Finally, StockNews.com lowered Perrigo from a “buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $33.00.
Check Out Our Latest Analysis on PRGO
Insider Transactions at Perrigo
In other news, EVP Ronald Craig Janish sold 7,800 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $27.44, for a total transaction of $214,032.00. Following the transaction, the executive vice president now directly owns 33,666 shares of the company’s stock, valued at $923,795.04. This represents a 18.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.70% of the company’s stock.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Recommended Stories
- Five stocks we like better than Perrigo
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
- What is Forex and How Does it Work?
- Why Call Option Traders Are Targeting This Dividend ETF Now
- How to buy stock: A step-by-step guide for beginners
- Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO – Free Report).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.